As of November 6, 2026, Mangoceuticals, Inc. is a publicly traded company (Nasdaq: MGRX). The largest holder reporting an active stake on Schedule 13D is Jacob D. Cohen, the chief executive and a director, at 21.5%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D/A, October 6, 2026).
Is this your company?
About to sign with, pay or invest in Mangoceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Mangoceuticals, Inc. a real, registered company?
- Mangoceuticals, Inc. files with the SEC under CIK 1938046 (its SEC filings).
- Its shares are listed under the ticker MGRX on Nasdaq (SEC company record).
- Incorporated in Texas; business address in Dallas, Texas, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under MANGOCEUTICALS, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Jacob D. Cohen (filed 2026-10-06).
Who are Mangoceuticals, Inc.'s owners and officers?
Mangoceuticals, Inc.: incorporated in Texas; business address in Dallas, Texas; industry Services-Misc Health & Allied Services, NEC (Schedule 13D/A, 2026-10-06).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-10-06 | Jacob D. Cohen | 21.5% |
| Schedule 13D/A, 2025-09-30 | Jacob D. Cohen | 14.6% |
Questions about who owns Mangoceuticals, Inc.
Who owns Mangoceuticals, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Mangoceuticals, Inc.: Jacob D. Cohen (21.5%, Schedule 13D/A, filed 2026-10-06).
When did Jacob D. Cohen buy into Mangoceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Jacob D. Cohen on this page is the Schedule 13D/A, filed 2025-09-30, reporting 14.6%; its latest, Schedule 13D/A filed 2026-10-06, reports 21.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Mangoceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Mangoceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mangoceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Mangoceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 3,305,000 shares (15.3% of shares outstanding), on a joint filing (Form 4, 2026-10-06).
- Tiger Cub Trust, a 10% owner: 3,305,000 shares (15.3% of shares outstanding), on a joint filing (Form 4, 2026-10-06).
- , the chief financial officer: 220,000 shares (1.0% of shares outstanding) (Form 4, 2026-10-06).
- , a director: 136,667 shares (0.63% of shares outstanding) (Form 4, 2025-09-12).
- , a director: 136,667 shares (0.63% of shares outstanding) (Form 4, 2025-09-12).
Shares outstanding: 21,567,422 as of 2026-08-13, from the company's latest SEC cover page.
How much has Mangoceuticals, Inc. raised?
Latest IPO step: Mangoceuticals, Inc. amended its IPO registration (S-1/A, 2026-01-23).
IPO filings: S-1/A, 2026-01-23, S-1, 2026-01-13, S-1, 2025-05-30, S-1, 2024-08-16; ticker MGRX on Nasdaq Capital Market.
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-10-01).
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/mangoceuticals